The phase 3 RELAY trial was designed to compare ramucirumab plus erlotinib and erlotinib alone and ramucirumab plus erlotinib showed superior PFS in patients with EGFR-mutated metastatic NSCLC (19.4 months vs. 12.4 months; HR: 0.59; p < 0.0001) [28]. Here, EGFR is linked to non-small cell lung carcinoma.